Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) has earned a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $16.90.

A number of brokerages have commented on ROIV. Deutsche Bank Aktiengesellschaft lifted their price target on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group lifted their price target on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday. Truist Financial reaffirmed a “buy” rating and set a $23.00 price target on shares of Roivant Sciences in a research report on Monday, March 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Friday, May 31st.

Check Out Our Latest Stock Report on ROIV

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Roivant Sciences during the 1st quarter valued at about $398,000. Cetera Advisors LLC purchased a new position in shares of Roivant Sciences in the 1st quarter valued at about $758,000. Whitefort Capital Management LP increased its stake in shares of Roivant Sciences by 50.3% in the 1st quarter. Whitefort Capital Management LP now owns 2,391,000 shares of the company’s stock valued at $25,201,000 after purchasing an additional 800,000 shares in the last quarter. Ionic Capital Management LLC purchased a new position in shares of Roivant Sciences in the 1st quarter valued at about $527,000. Finally, Kennedy Capital Management LLC purchased a new position in shares of Roivant Sciences in the 1st quarter valued at about $276,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 1.0 %

Roivant Sciences stock opened at $10.69 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24. The stock has a market capitalization of $7.90 billion, a price-to-earnings ratio of 2.11 and a beta of 1.25. Roivant Sciences has a 1-year low of $8.24 and a 1-year high of $13.24. The business has a fifty day moving average price of $10.93 and a 200-day moving average price of $10.86.

Roivant Sciences Company Profile

(Get Free Report

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

See Also

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.